EOLS News and Press, Evolus Inc. From 08/23/23

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 83,555 shares of Evolus common st...

Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (C...

Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline ex...

Company launches bold rebrand of Jeuveau ® (prabotulinumtoxinA-xvfs), a modern-made neurotoxin dedicated exclusively for aesthetics Jeuveau ® has been the fastest-growing neurotoxin in the U.S. for two consecutive years in 2021 and 2022 1 Evolus, Inc. (NA...

2023-08-02 23:10:24 ET Evolus, Inc. (EOLS) Q2 2023 Earnings Conference Call August 02, 2023 04:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO ...

2023-08-02 16:22:27 ET Evolus press release ( NASDAQ: EOLS ): Q2 GAAP EPS of -$0.32. Revenue of $49.3M (+32.5% Y/Y). Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 Million. Company continues to expect its adjusted gross profit margin for the full year 2...

Q2 2023 Net Revenue of $49.3 Million, Up 33% from Q2 2022 Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 Million On Track to Achieving Sustained Profitability with Existing Cash Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on b...

2023-07-31 02:26:55 ET Evolus ( NASDAQ: EOLS ) achieved Q2 revenue of $49.3M, growing 33% Y/Y and 10 percentage points above Q1 2023. The company also raised FY 2023 net revenue guidance to $185M-195M from $180M-190M. The company showed record growth and all-ti...

Evolus, Inc. (NASDAQ: EOLS) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 29.16% on the day to $10.1. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patie...

2023-07-27 11:42:19 ET Shares of Evolus (NASDAQ: EOLS) were up more than 25% as of 11 a.m. ET after the company reported record quarterly revenue and increased guidance. The stock is up 31% so far this year. Evolus is a customer-centric healthcare aesthetics company. Its lea...